| __timestamp | MannKind Corporation | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 152500000 |
| Thursday, January 1, 2015 | 29674000 | 187800000 |
| Friday, January 1, 2016 | 14917000 | 184000000 |
| Sunday, January 1, 2017 | 14118000 | 167700000 |
| Monday, January 1, 2018 | 8737000 | 218600000 |
| Tuesday, January 1, 2019 | 6900000 | 187400000 |
| Wednesday, January 1, 2020 | 6248000 | 177700000 |
| Friday, January 1, 2021 | 12312000 | 122000000 |
| Saturday, January 1, 2022 | 19721000 | 123100000 |
| Sunday, January 1, 2023 | 31283000 | 122500000 |
Cracking the code
In the competitive landscape of pharmaceutical innovation, research and development (R&D) spending is a critical indicator of a company's commitment to future growth. Over the past decade, Perrigo Company plc and MannKind Corporation have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Perrigo consistently outspent MannKind, with its R&D expenses peaking in 2018 at nearly 2.2 times MannKind's highest expenditure in 2014. Despite a 70% reduction in MannKind's R&D spending from 2014 to 2019, the company has shown a resurgence, increasing its investment by over 400% from 2019 to 2023. Meanwhile, Perrigo's R&D spending has remained relatively stable, with a slight decline of around 20% from its 2018 peak. This analysis highlights the dynamic nature of R&D strategies in the pharmaceutical sector, reflecting each company's unique approach to innovation and market adaptation.
AbbVie Inc. vs Perrigo Company plc: Strategic Focus on R&D Spending
R&D Spending Showdown: Novartis AG vs Perrigo Company plc
Bristol-Myers Squibb Company vs Perrigo Company plc: Strategic Focus on R&D Spending
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
Comparing Innovation Spending: Summit Therapeutics Inc. and Perrigo Company plc
R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Opthea Limited vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.